Dynamic quotes: Off
|
ETFs with ALXN as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 6.62% | iShares NASDAQ Biotechnology Index Fund (IBB) | +44.91 (32.87%) |
| 5.06% | PowerShares Dynamic Biotech &Genome (PBE) | +1.82 (7.60%) |
| 3.72% | Columbia Select Large Cap Growth ETF (RWG) | +7.33 (26.25%) |
| 2.8% | PowerShares Dynamic Heathcare (PTH) | +1.74 (5.45%) |
| 2.51% | SPDR Series Trust SPDR S&P Biotech ETF (XBI) | +22.14 (25.27%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris® (eculizumab) is the first and only therapeutic approved for patients with two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, and atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. ... More ...
Analyst Info |
|
| Annual EPS Est: | $1.86 |
| Quarterly EPS Est: | 0.6 |
| PEG Ratio: | 1.51 |
|
Mean Recommendation: View Summary / View All |
1.45 |
Data is provided by Zacks Investment Research

